ORIC Pharmaceuticals (NASDAQ:ORIC) Rating Reiterated by Cantor Fitzgerald
Cantor Fitzgerald reiterated their overweight rating on shares of ORIC Pharmaceuticals (NASDAQ:ORIC – Free Report) in a research report released on Thursday morning, Benzinga reports. Several other analysts have also commented on the stock. HC Wainwright raised their price objective on shares of ORIC Pharmaceuticals from $15.00 to $21.00 and gave the stock a buy […]
More Stories
Washington Monument Illumination Kicks Off Yearlong Celebration of America’s 250th Birthday
By Jeff Louderback On the campaign trail in his bid for a White House return, President Donald Trump pledged to...
Trump Vows to Intervene if Iran Kills Protestors
By Guy Birchall President Donald Trump on Jan. 2 vowed to come to the aid of protesters in Iran if...
Emily in Paris Season 6: Netflix Renewal Status and Expectations
Emily in Paris is a story of a 29-year-old girl who has shifted from Chicago to Paris for a job...
Kate Winslet’s Net Worth in 2026: Assets, Salary, and Relationships
With a huge net worth, Kate Winslet has been enjoying a fantastic career that has seen her successfully combine blockbusters...
NIL (Name, Image, and Likeness): Top 20 Highest-Paid College Athletes
The NCAA (National Collegiate Athletic Association) is a US-based government body that regulates the rules of sports in colleges and...
Porsche Recalls More than 173,500 Vehicles for Rear-Camera Malfunction
By Rob Sabo Porsche Cars North America, Inc. has issued a recall of 173,538 vehicles manufactured during the past six...